Angiodynamics Stock Price, News & Analysis

AngioDynamics, Inc. (NASDAQ: ANGO) has announced that President and CEO Jim Clemmer, along with Executive VP and CFO Stephen Trowbridge, will present at the Needham 22nd Annual Virtual Healthcare Conference on April 17, 2023, at 8:00 a.m. ET. The presentation aims to showcase the company’s innovative medical technologies focused on enhancing blood flow and cancer treatment options, ultimately improving patient quality of life.

A live webcast will be available in the “Investors” section of AngioDynamics’ website, with a replay accessible post-event. The presentation highlights the company’s commitment to addressing unmet patient needs through its transformative medical solutions.

AngioDynamics reported third-quarter fiscal 2023 net sales of $80.7 million, a 9.1% increase from last year. Med Tech sales grew 16.6% to $22.9 million, driven by Auryon and NanoKnife products. However, gross margin decreased to 50.2%, down 200 basis points year-over-year. The company reported a net loss of $9.5 million or $0.24 per share, compared to a loss of $5.0 million a year ago. Adjusted EBITDA was $4.3 million, falling from $6.7 million in Q3 2022. Due to lower AngioVac sales, the fiscal 2023 guidance for net sales was revised downward to $338 million to $342 million.

AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 of fiscal year 2023 on March 30, 2023, before the market opens. A conference call is scheduled for 8:00 a.m. ET that same day to discuss the results. Interested participants can call 1-877-407-0784 (domestic) or +1-201-689-8560 (international) using passcode 13737051. The call will also be available via webcast on the AngioDynamics website, with a replay accessible beginning at 11:00 a.m. ET on the same day until April 6, 2023.

AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced participation in three investor conferences in March 2023. The Raymond James Institutional Investors Conference will be held on March 6 at 8:05 a.m. ET in Orlando, FL. Following that, AngioDynamics will engage in a Fireside Chat at the Oppenheimer Virtual Healthcare Conference on March 13 at 9:20 a.m. ET. Lastly, they will present at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 21 at 4:30 p.m. ET. Live webcasts will be available on their website, with replays after each event.

AngioDynamics (ANGO) reported a strong Q2 FY2023, with net sales of $85.4 million, a 9.1% increase year-over-year. Med Tech sales surged 29.7% to $24.5 million, driven by Auryon and NanoKnife products. However, the company posted a GAAP loss per share of $0.21, unchanged from the prior year. Gross margin increased to 52.8%, despite macroeconomic pressures like labor shortages. For H1 FY2023, net sales rose 7.5% to $167 million. AngioDynamics reaffirmed its FY2023 guidance for net sales between $342 million and $348 million.

AngioDynamics, Inc. (NASDAQ: ANGO) announced that Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will present at the J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. This presentation focuses on AngioDynamics' commitment to transforming medical technology aimed at restoring vascular health and enhancing cancer treatment options. A live webcast will be available on the company's website, with a replay following the event.